Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 82 articles:
HTML format
Text format



Single Articles


    January 2018
  1. HAN S, Kim D, Shivakumar M, Lee YJ, et al
    The effects of alternative splicing on miRNA binding sites in bladder cancer.
    PLoS One. 2018;13:e0190708.
    PubMed     Text format     Abstract available


  2. SATHE A, Chalaud G, Oppolzer I, Wong KY, et al
    Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
    PLoS One. 2018;13:e0190854.
    PubMed     Text format     Abstract available


  3. KIM M, Oh SJ, Kwak C, Kim HH, et al
    Psychometric validation study of the Korean version of the Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index.
    PLoS One. 2018;13:e0190570.
    PubMed     Text format     Abstract available


  4. BARBOSA ALA, Vermeulen SHHM, Aben KK, Grotenhuis AJ, et al
    Smoking intensity and bladder cancer aggressiveness at diagnosis.
    PLoS One. 2018;13:e0194039.
    PubMed     Text format     Abstract available


  5. XIA Y, Liu Z, Yu W, Zhou S, et al
    The prognostic significance of long noncoding RNAs in bladder cancer: A meta-analysis.
    PLoS One. 2018;13:e0198602.
    PubMed     Text format     Abstract available


  6. BECKFORD VERA DR, Smith CC, Bixby LM, Glatt DM, et al
    Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors.
    PLoS One. 2018;13:e0193832.
    PubMed     Text format     Abstract available


  7. HARTANA CA, Ahlen Bergman E, Zirakzadeh AA, Krantz D, et al
    Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGFbeta2 mediated pathway.
    PLoS One. 2018;13:e0200079.
    PubMed     Text format     Abstract available


    January 2017
  8. MATSUO T, Miyata Y, Asai A, Sagara Y, et al
    Green Tea Polyphenol Induces Changes in Cancer-Related Factors in an Animal Model of Bladder Cancer.
    PLoS One. 2017;12:e0171091.
    PubMed     Text format     Abstract available


  9. XIONG Y, Li J, Ma S, Ge J, et al
    A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer.
    PLoS One. 2017;12:e0170819.
    PubMed     Text format     Abstract available


  10. SHIN SS, Song JH, Hwang B, Noh DH, et al
    HSPA6 augments garlic extract-induced inhibition of proliferation, migration, and invasion of bladder cancer EJ cells; Implication for cell cycle dysregulation, signaling pathway alteration, and transcription factor-associated MMP-9 regulation.
    PLoS One. 2017;12:e0171860.
    PubMed     Text format     Abstract available


  11. VAN KESSEL KE, van de Werken HJ, Lurkin I, Ziel-van der Made AC, et al
    A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.
    PLoS One. 2017;12:e0174039.
    PubMed     Text format     Abstract available


  12. IDE H, Inoue S, Miyamoto H
    Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies.
    PLoS One. 2017;12:e0174746.
    PubMed     Text format     Abstract available


  13. XIE JY, Chen PC, Zhang JL, Gao ZS, et al
    The prognostic significance of DAPK1 in bladder cancer.
    PLoS One. 2017;12:e0175290.
    PubMed     Text format     Abstract available


  14. ORRE M, Latorzeff I, Flechon A, Roubaud G, et al
    Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study.
    PLoS One. 2017;12:e0174978.
    PubMed     Text format     Abstract available


  15. HORI S, Miyake M, Tatsumi Y, Onishi S, et al
    Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.
    PLoS One. 2017;12:e0175494.
    PubMed     Text format     Abstract available


  16. REULEN RC, de Vogel S, Zhong W, Zhong Z, et al
    Physical activity and risk of prostate and bladder cancer in China: The South and East China case-control study on prostate and bladder cancer.
    PLoS One. 2017;12:e0178613.
    PubMed     Text format     Abstract available


  17. AFSHARI M, Janbabaei G, Bahrami MA, Moosazadeh M, et al
    Opium and bladder cancer: A systematic review and meta-analysis of the odds ratios for opium use and the risk of bladder cancer.
    PLoS One. 2017;12:e0178527.
    PubMed     Text format     Abstract available


  18. SU YL, Hsieh MC, Chiang PH, Sung MT, et al
    Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma.
    PLoS One. 2017;12:e0169657.
    PubMed     Text format     Abstract available


  19. DROOP J, Szarvas T, Schulz WA, Niedworok C, et al
    Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma.
    PLoS One. 2017;12:e0176287.
    PubMed     Text format     Abstract available


  20. HUANG P, Lan M, Peng AF, Yu QF, et al
    Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer.
    PLoS One. 2017;12:e0183835.
    PubMed     Text format     Abstract available


  21. DOWELL AC, Cobby E, Wen K, Devall AJ, et al
    Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.
    PLoS One. 2017;12:e0184841.
    PubMed     Text format     Abstract available


  22. DAI YC, Wang SC, Haque MM, Lin WH, et al
    The interaction of arsenic and N-butyl-N-(4-hydroxybutyl)nitrosamine on urothelial carcinogenesis in mice.
    PLoS One. 2017;12:e0186214.
    PubMed     Text format     Abstract available


  23. HUANG JY, Wang R, Gao YT, Yuan JM, et al
    ABO blood type and the risk of cancer - Findings from the Shanghai Cohort Study.
    PLoS One. 2017;12:e0184295.
    PubMed     Text format     Abstract available


  24. KWAK YK, Lee SW, Kay CS, Park HH, et al
    Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose.
    PLoS One. 2017;12:e0183339.
    PubMed     Text format     Abstract available


  25. GROMOVA I, Svensson S, Gromov P, Moreira JMA, et al
    Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer.
    PLoS One. 2017;12:e0188827.
    PubMed     Text format     Abstract available


  26. SASAKI N, Ishi K, Kudo N, Nakayama SMM, et al
    Spatial and temporal profile of cisplatin delivery by ultrasound-assisted intravesical chemotherapy in a bladder cancer model.
    PLoS One. 2017;12:e0188093.
    PubMed     Text format     Abstract available


  27. BOGNAR Z, Fekete K, Antus C, Hocsak E, et al
    Desethylamiodarone-A metabolite of amiodarone-Induces apoptosis on T24 human bladder cancer cells via multiple pathways.
    PLoS One. 2017;12:e0189470.
    PubMed     Text format     Abstract available


  28. TAE BS, Jeong CW, Kwak C, Kim HH, et al
    Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
    PLoS One. 2017;12:e0189354.
    PubMed     Text format     Abstract available


  29. LINDQUIST KJ, Sanford T, Friedlander TW, Paris PL, et al
    Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors.
    PLoS One. 2017;12:e0187975.
    PubMed     Text format     Abstract available


    January 2016
  30. BERRONDO C, Flax J, Kucherov V, Siebert A, et al
    Expression of the Long Non-Coding RNA HOTAIR Correlates with Disease Progression in Bladder Cancer and Is Contained in Bladder Cancer Patient Urinary Exosomes.
    PLoS One. 2016;11:e0147236.
    PubMed     Text format     Abstract available


  31. WANG S, Zhang H, Scharadin TM, Zimmermann M, et al
    Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
    PLoS One. 2016;11:e0146256.
    PubMed     Text format     Abstract available


  32. JOHNSON DT, Hooker E, Luong R, Yu EJ, et al
    Conditional Expression of the Androgen Receptor Increases Susceptibility of Bladder Cancer in Mice.
    PLoS One. 2016;11:e0148851.
    PubMed     Text format     Abstract available


  33. HATAKEYAMA S, Koie T, Narita T, Hosogoe S, et al
    Renal Function Outcomes and Risk Factors for Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer.
    PLoS One. 2016;11:e0149544.
    PubMed     Text format     Abstract available


  34. WARD DG, Baxter L, Gordon NS, Ott S, et al
    Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer.
    PLoS One. 2016;11:e0149756.
    PubMed     Text format     Abstract available


  35. LORENZATTI HILES G, Bucheit A, Rubin JR, Hayward A, et al
    ADAM15 Is Functionally Associated with the Metastatic Progression of Human Bladder Cancer.
    PLoS One. 2016;11:e0150138.
    PubMed     Text format     Abstract available


  36. HATAKEYAMA S, Koie T, Narita T, Hosogoe S, et al
    Correction: Renal Function Outcomes and Risk Factors for Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer.
    PLoS One. 2016;11:e0151742.
    PubMed     Text format     Abstract available


  37. GUANCIAL EA, Kilari D, Xiao GQ, Abu-Farsakh SH, et al
    Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    PLoS One. 2016;11:e0155503.
    PubMed     Text format     Abstract available


  38. CHEN MF, Lin PY, Wu CF, Chen WC, et al
    Correction: IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder Cancer.
    PLoS One. 2016;11:e0155774.
    PubMed     Text format     Abstract available


  39. WANG S, Lei T, Zhang M
    The Reversal Effect and Its Mechanisms of Tetramethylpyrazine on Multidrug Resistance in Human Bladder Cancer.
    PLoS One. 2016;11:e0157759.
    PubMed     Text format     Abstract available


  40. TIAN Y, Ma Z, Chen Z, Li M, et al
    Clinicopathological and Prognostic Value of Ki-67 Expression in Bladder Cancer: A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0158891.
    PubMed     Text format     Abstract available


  41. WU J, Huang Q, Meng D, Huang M, et al
    A Functional rs353293 Polymorphism in the Promoter of miR-143/145 Is Associated with a Reduced Risk of Bladder Cancer.
    PLoS One. 2016;11:e0159115.
    PubMed     Text format     Abstract available


  42. CHATZIHARALAMBOUS D, Lygirou V, Latosinska A, Stravodimos K, et al
    Analytical Performance of ELISA Assays in Urine: One More Bottleneck towards Biomarker Validation and Clinical Implementation.
    PLoS One. 2016;11:e0149471.
    PubMed     Text format     Abstract available


  43. MILLER A, Burson H, Soling A, Roughan J, et al
    Welfare Assessment following Heterotopic or Orthotopic Inoculation of Bladder Cancer in C57BL/6 Mice.
    PLoS One. 2016;11:e0158390.
    PubMed     Text format     Abstract available


  44. DUAN F, Yu Y, Guan R, Xu Z, et al
    Vitamin K2 Induces Mitochondria-Related Apoptosis in Human Bladder Cancer Cells via ROS and JNK/p38 MAPK Signal Pathways.
    PLoS One. 2016;11:e0161886.
    PubMed     Text format     Abstract available


  45. GARCIA MM, Gottschalk AR, Brajtbord J, Konety BR, et al
    Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes.
    PLoS One. 2016;11:e0164558.
    PubMed     Text format     Abstract available


  46. XIE J, Codd C, Mo K, He Y, et al
    Differential Adverse Event Profiles Associated with BCG as a Preventive Tuberculosis Vaccine or Therapeutic Bladder Cancer Vaccine Identified by Comparative Ontology-Based VAERS and Literature Meta-Analysis.
    PLoS One. 2016;11:e0164792.
    PubMed     Text format     Abstract available


  47. KIM D, Choi Y, Ireland J, Foreman O, et al
    Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers.
    PLoS One. 2016;11:e0165856.
    PubMed     Text format     Abstract available


  48. LIMA L, Gaiteiro C, Peixoto A, Soares J, et al
    Reference Genes for Addressing Gene Expression of Bladder Cancer Cell Models under Hypoxia: A Step Towards Transcriptomic Studies.
    PLoS One. 2016;11:e0166120.
    PubMed     Text format     Abstract available


  49. LONG X, Zu X, Li Y, He W, et al
    Epidermal Growth Factor Receptor and Ki-67 as Predictive Biomarkers Identify Patients Who Will Be More Sensitive to Intravesical Instillations for the Prevention of Bladder Cancer Recurrence after Radical Nephroureterectomy.
    PLoS One. 2016;11:e0166884.
    PubMed     Text format     Abstract available


  50. DAI L, Ma C, Zhang Z, Zeng S, et al
    DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0167228.
    PubMed     Text format     Abstract available


  51. KANEMOTO K, Fukuta K, Kawai N, Tozawa K, et al
    Genomic Landscape of Experimental Bladder Cancer in Rodents and Its Application to Human Bladder Cancer: Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype.
    PLoS One. 2016;11:e0167374.
    PubMed     Text format     Abstract available


  52. WU Z, Wang C, Zhang Z, Liu W, et al
    High Expression of Derlin-1 Is Associated with the Malignancy of Bladder Cancer in a Chinese Han Population.
    PLoS One. 2016;11:e0168351.
    PubMed     Text format     Abstract available


  53. LI M, Wang L
    The Associations of Psychological Stress with Depressive and Anxiety Symptoms among Chinese Bladder and Renal Cancer Patients: The Mediating Role of Resilience.
    PLoS One. 2016;11:e0154729.
    PubMed     Text format     Abstract available


  54. MASOOMPOUR SM, Lankarani KB, Honarvar B, Tabatabaee SH, et al
    Changing Epidemiology of Common Cancers in Southern Iran, 2007-2010: A Cross Sectional Study.
    PLoS One. 2016;11:e0155669.
    PubMed     Text format     Abstract available


    January 2015
  55. WANG YL, Jiang B, Yin FF, Shi HQ, et al
    Perioperative Blood Transfusion Promotes Worse Outcomes of Bladder Cancer after Radical Cystectomy: A Systematic Review and Meta-Analysis.
    PLoS One. 2015;10:e0130122.
    PubMed     Text format     Abstract available


  56. ANDERSSON E, Dahmcke CM, Steven K, Larsen LK, et al
    Filtration Device for On-Site Collection, Storage and Shipment of Cells from Urine and Its Application to DNA-Based Detection of Bladder Cancer.
    PLoS One. 2015;10:e0131889.
    PubMed     Text format     Abstract available


  57. BOSTROM MM, Irjala H, Mirtti T, Taimen P, et al
    Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer.
    PLoS One. 2015;10:e0133552.
    PubMed     Text format     Abstract available


  58. YANG G, Xu Z, Lu W, Li X, et al
    Quantitative Analysis of Differential Proteome Expression in Bladder Cancer vs. Normal Bladder Cells Using SILAC Method.
    PLoS One. 2015;10:e0134727.
    PubMed     Text format     Abstract available


  59. KIM YW, Yun SJ, Jeong P, Kim SK, et al
    The c-MET Network as Novel Prognostic Marker for Predicting Bladder Cancer Patients with an Increased Risk of Developing Aggressive Disease.
    PLoS One. 2015;10:e0134552.
    PubMed     Text format     Abstract available


  60. YANG Y, Qu A, Liu J, Wang R, et al
    Serum miR-210 Contributes to Tumor Detection, Stage Prediction and Dynamic Surveillance in Patients with Bladder Cancer.
    PLoS One. 2015;10:e0135168.
    PubMed     Text format     Abstract available


  61. PAN CX, Zhang H, Tepper CG, Lin TY, et al
    Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
    PLoS One. 2015;10:e0134346.
    PubMed     Text format     Abstract available


  62. BRITO RB, Malta CS, Souza DM, Matheus LH, et al
    1-Methyl-D-Tryptophan Potentiates TGF-beta-Induced Epithelial-Mesenchymal Transition in T24 Human Bladder Cancer Cells.
    PLoS One. 2015;10:e0134858.
    PubMed     Text format     Abstract available


  63. SCHWENDER H, Selinski S, Blaszkewicz M, Marchan R, et al
    Correction: Distinct SNP Combinations Confer Susceptibility to Urinary Bladder Cancer in Smokers and Non-Smokers.
    PLoS One. 2015;10:e0137937.
    PubMed     Text format     Abstract available


  64. KITCHEN MO, Bryan RT, Haworth KE, Emes RD, et al
    Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.
    PLoS One. 2015;10:e0137003.
    PubMed     Text format     Abstract available


  65. FUKUHARA H, Kureishi M, Khoda T, Inoue K, et al
    The Utility of a Flexible Fluorescence-Cystoscope with a Twin Mode Monitor for the 5-Aminolevulinic Acid-Mediated Photodynamic Diagnosis of Bladder Cancer.
    PLoS One. 2015;10:e0136416.
    PubMed     Text format     Abstract available


  66. DHAWAN D, Paoloni M, Shukradas S, Choudhury DR, et al
    Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer.
    PLoS One. 2015;10:e0136688.
    PubMed     Text format     Abstract available


  67. COSTA C, Pereira S, Lima L, Peixoto A, et al
    Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
    PLoS One. 2015;10:e0141253.
    PubMed     Text format     Abstract available


  68. CHEN MC, Chen YL, Lee CF, Hung CH, et al
    Supplementation of Magnolol Attenuates Skeletal Muscle Atrophy in Bladder Cancer-Bearing Mice Undergoing Chemotherapy via Suppression of FoxO3 Activation and Induction of IGF-1.
    PLoS One. 2015;10:e0143594.
    PubMed     Text format     Abstract available


  69. ZHANG X, Zhang Y, Liu X, Fang A, et al
    MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin.
    PLoS One. 2015;10:e0143441.
    PubMed     Text format     Abstract available


  70. CHAWKI S, Ploussard G, Montlahuc C, Verine J, et al
    Bladder Cancer in HIV-infected Adults: An Emerging Issue? Case-Reports and Systematic Review.
    PLoS One. 2015;10:e0144237.
    PubMed     Text format     Abstract available


  71. SUN L, Lu J, Niu Z, Ding K, et al
    A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer.
    PLoS One. 2015;10:e0144484.
    PubMed     Text format     Abstract available


  72. CAO L, Tong H, Xu G, Liu P, et al
    Systemic lupus erythematous and malignancy risk: a meta-analysis.
    PLoS One. 2015;10:e0122964.
    PubMed     Text format     Abstract available


  73. LI Y, Yu G, Li Q, Wang W, et al
    Construction of a BALB/c-Nu Mouse Model of Invasive Bladder Carcinoma and Preliminary Studies on the Treatment of Bladder Tumors through Internal Iliac Arterial Infusion of Albumin-Bound Arsenic Trioxide (As2O3).
    PLoS One. 2015;10:e0124959.
    PubMed     Text format     Abstract available


  74. SHANG W, Ning Y, Xu X, Li M, et al
    Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies.
    PLoS One. 2015;10:e0126016.
    PubMed     Text format     Abstract available


  75. GEVAERT T, Moles Lopez X, Sagaert X, Libbrecht L, et al
    Morphometric and quantitative immunohistochemical analysis of disease-related changes in the upper (suburothelial) lamina propria of the human bladder dome.
    PLoS One. 2015;10:e0127020.
    PubMed     Text format     Abstract available


  76. ARDELT PU, Ebbing J, Adams F, Reiss C, et al
    An anti-ubiquitin antibody response in transitional cell carcinoma of the urinary bladder.
    PLoS One. 2015;10:e0118646.
    PubMed     Text format     Abstract available


  77. MASSARI F, Bria E, Ciccarese C, Munari E, et al
    Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder.
    PLoS One. 2015;10:e0127908.
    PubMed     Text format     Abstract available


  78. WU S, Xu R, Wan Q, Zhu X, et al
    Assessment of the potential diagnostic role of anaplastic lymphoma kinase for inflammatory myofibroblastic tumours: a meta-analysis.
    PLoS One. 2015;10:e0125087.
    PubMed     Text format     Abstract available


  79. JOUNG JY, Lim J, Oh CM, Jung KW, et al
    Risk of Second Primary Cancer among Prostate Cancer Patients in Korea: A Population-Based Cohort Study.
    PLoS One. 2015;10:e0140693.
    PubMed     Text format     Abstract available


    January 2014
  80. LI X, Choi WW, Yan R, Yu H, et al
    The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
    PLoS One. 2014;9:e105326.
    PubMed     Text format     Abstract available


  81. ALEXANDER RE, Williamson SR, Richey J, Lopez-Beltran A, et al
    The Expression Patterns of p53 and p16 and an Analysis of a Possible Role of HPV in Primary Adenocarcinoma of the Urinary Bladder.
    PLoS One. 2014;9:e95724.
    PubMed     Text format     Abstract available


  82. HONG S, Kim SC, Kwon T, Jeong IG, et al
    Is bladder tumor location associated with prostate cancer detection after intravesical bacillus calmette-guerin instillation?
    PLoS One. 2014;9:e103791.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: